Design and Development of Nanobased Delivery System Bearing Antineoplastic Agent for Breast Cancer

Abstract

Breast cancer remains one of the leading causes of cancer-related mortality in women worldwide, with existing therapies often limited by systemic toxicity, multidrug resistance, and poor therapeutic selectivity. Nanotechnology-based drug delivery systems have emerged as a promising alternative to enhance therapeutic efficacy while minimizing adverse effects. This research aimed to formulate and optimize a nanocarrier system encapsulating a selected antineoplastic drug, evaluate its physicochemical and biological properties, and analyze its therapeutic performance across 1000 biological samples.

The study involves systematic formulation using advanced nanotechnology techniques, followed by characterization through DLS, SEM, TEM, FTIR, DSC, and XRD. Biological evaluation includes in vitro cytotoxicity, cellular uptake, and apoptosis studies, complemented by in vivo pharmacokinetics and biodistribution in xenograft models. A comparative assessment with free drug formulations highlights the superiority of the nanoformulation in targeted tumor delivery and reduced systemic toxicity. Data from 1000 samples provide statistical robustness for survival analysis, toxicity assessment, and therapeutic outcome validation.

The findings contribute to bridging the gap between laboratory-scale nanotechnology innovations and clinically relevant breast cancer therapies. The developed system offers potential for future translational research, personalized medicine applications, and regulatory pathways toward safer and more effective cancer treatment.